Table 2.

Dabrafenib efficacy

	Part 1			Part 2
Characteristic	Dabrafenib 3.75 mg/kg (n = 3)	Dabrafenib 4.5 mg/kg (n = 6)	Dabrafenib 5.25 mg/kg (n = 6)	Dabrafenib RP2D (n = 17)	All patients treated with dabrafenib at RP2D (n = 24)	All patients with LGG (N = 32)
Independent review^a
Best overall response, n (%)
Complete response	0	1 (17)	0	0	0	1 (3)
Partial response	2 (67)	2 (33)	2 (33)	7 (41)	9 (38)	13 (41)
Stable disease^b	1 (33)	3 (50)	4 (67)	8 (47)	13 (54)	16 (50)
Progressive disease	0	0	0	2 (12)	2 (8)	2 (6)
Objective response, n (%) [95% CI]	2 (67) [9–99]	3 (50) [12–88]	2 (33) [4–78]	7 (41) [18–67]	9 (38) [19–59]	14 (44) [26–62]
Median duration of response (range), months	—	—	—	—	11.0 (3.7–14.5)	11.0 (7.4–14.5)
Disease control, n (%) [95% CI]	3 (100) [29–100]	5 (83) [36–100]	5 (83) [36–100]	12 (71) [44–90]	18 (75) [53–90]	25 (78) [60–91]
Median progression-free survival (95% CI), months^c	35 (15–NE)	(NE–NE)	13 (13–NE)	(NE–NE)	14 (13–NE)	35 (13–NE)
1-year progression-free survival rate (95% CI), %^c	100 (100–100)	80 (20–97)	100 (100–100)	78 (46–92)	79 (53–92)	85 (64–94)

Abbreviation: NE, not estimable.
↵^aUsing RANO criteria.
↵^bIncludes 5 patients with independent review of stable disease but lacking any confirmation scan results.
↵^cKaplan–Meier estimate.